ENZO BIOCHEM INC
enzo.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Jun 16, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.
10-Q for Q3 FY2025, filed Jun 16, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells labeling and detection products, including antibodies, genomic probes and assays, to academic and clinical researchers, drug developers and diagnostic manufacturers.
10-K for FY2024, filed Oct 29, 2024
How Did They Make Money?
Customers buy single-use products used to identify genomic information; Enzo earns the sale when products ship or are delivered, and payment terms range from 30 to 90 days.
10-K for FY2024, filed Oct 29, 2024The Company generates revenue from the sale of our single-use products used in the identification of genomic information. Revenue is…View ↗
$31.9M
-
10-K for FY2024, filed Oct 30, 2024
$31.9M ↗
Who Were Their Customers?
Researchers can order directly under Enzo Life Sciences or through Axxora; manufacturers buy under supply agreements, while distributors serve customers in other major markets.
10-K for FY2024, filed Oct 29, 2024
Did Revenues Turn Into Profits?
No. It lost $26.1M in FY2024.
10-K for FY2024, filed Oct 30, 2024
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Jun 17, 2025
−$2.8MView ↗
- ▼ −8% (Loss)
- vs −$3M in Q3 FY2024
-
Aug 20, 2025
Merger closed, ending public trading and changing control of Enzo
Enzo's shares converted into cash at $0.70 each, and its common stock stopped trading on over-the-counter markets.
Sources
8-K, filed Aug 20, 2025
Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of the common stock of the…View ↗
Shrank. Revenue fell 58% in 4 years, from $76M in FY2020 to $31.9M in FY2024, about 20% a year.
Clinical testing ended
The older report described a clinical reference laboratory serving physicians, medical centers, other labs and pharmaceutical companies. The latest describes Life Sciences as the primary business after Clinical Labs' assets were sold and clinical services ended.
10-K for FY2021, filed Oct 12, 2021 10-K for FY2024, filed Oct 29, 2024Enzo Clinical Lab is a clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other…View ↗
Enzo Biochem, Inc. (the “Company”, “we”, “our” or “Enzo”) has operated as a life sciences company for over 45 years. The primary business…View ↗
In prior years, the Company also had a clinical lab business, operated as Enzo Clinical Labs, Inc. (“Clinical Labs”). In July 2023, we sold…View ↗
The Company has operated as a life sciences company for over 45 years. The primary business of Enzo today is conducted through its Enzo…View ↗
Loading...
